Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 137

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 137
---
 a clawback policy in order to comply with federal securities laws. As such, we have adopted a clawback policy in which we may seek the recovery or forfeiture of incentive compensation paid by us, including cash, equity or equity-based compensation, in the event we restate our financial statements under certain circumstances. The clawback policy applies to our Section 16 officers, any employee who was eligible to receive incentive compensation and whose conduct contributed to the need for a restatement, and any other former Section 16 officer or other employee who contributed to the need for such restatement.

Board of Directors Role in Risk Oversight

Members of the board of directors have periodic meetings with management and the Company’s independent auditors to perform risk oversight with respect to the Company’s internal control processes. The Company believes that the board of directors’ role in risk oversight does not materially affect the leadership structure of the Company. The Company believes that its founders, leadership team and members of the board of directors exemplify diversity and inclusivity with respect to race, sex and ethnic origin. The board of directors presently has two diverse directors and is in the process of reviewing and vetting a female candidate to serve as a director. As such, the Company anticipates being in full compliance with Nasdaq’s newly adopted diversity requirements by the end of its first year of listing.

| 82 |

<div align='center'>EXECUTIVE AND DIRECTOR COMPENSATION</div>

Summary Compensation Table

The table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and certain of our other executive officers for 2024 and 2023.

| Name and principal position         |     | Year |      |     | Salary ($) |         |     | Bonus ($) |         |     | Stock      
 Awards ($) |         |     | Option     
 Awards ($) |   |     | Non-Equity Incentive Plan Compensation 
 ($)                                    |   |     | Nonqualified                       
 Deferred Compensation Earnings ($) |   |     | All                    
 Other Compensation ($) |   |     | Total ($) |         |
| Anatoly Dritschilo M.D., CEO        |     |      | 2024 |     |            | 274,000 |     |           |       0 |     |            |       - |     |            | - |     |                                        | - |     |                                    | - |     |                        | - |     |           | 274,000 |
|                                     |     |      | 2023